All Posts Tagged With: "and thyroid autoantibody assays"

Who needs thyroid? That issue will be discussed by high level academicians who are lab experts who are discussing some new ways to evaluate thyroid function. Of course the book by Mark Starr MD called Hypothyroidism Type Two will not be on this agenda but these are some enlighten experts who see that current thyroid testing leaves much to be desired. 

Garry F. Gordon MD,DO,MD(H)
President, Gordon Research Institute
www.gordonresearch.com

Link: http://www.aacc.org/events/meetings/Pages/6201.aspx

Excerpt:

Approximately 20 million Americans now suffer from some form of thyroid disease, but experts estimate that about 13 million of them have not been diagnosed. With so many affected by a dysfunctional thyroid gland, thyroid function testing is becoming increasingly important to support both the diagnosis and management of thyroid disease. Unfortunately, controversy still exists concerning the upper limit of the TSH reference range and there is still confusion over when to use other thyroid immunoassays in the management of patients suspected of thyroid disease. Additionally, tandem mass spectrometry is rapidly emerging as a technology that could challenge labs’ reliance on traditional immunoassays for T4 and FT4. 

During this interactive webinar, you will hear the most up-to-date information on a variety of contemporary issues related to testing for thyroid disease. 

Who needs thyroid? That issue will be discussed by high level academicians who are lab experts who are discussing some new ways to evaluate thyroid function. Of course the book by Mark Starr MD called Hypothyroidism Type Two will not be on this agenda but these are some enlighten experts who see that current thyroid testing leaves much to be desired. 

Garry F. Gordon MD,DO,MD(H)
President, Gordon Research Institute
www.gordonresearch.com

Thyroid Testing Webinar

Contemporary Issues in Thyroid Disease Management
Wednesday, December 1, 2010
2:00–3:30pm Eastern U.S. Time

Register here: http://www.aacc.org/events/meetings/Pages/6201.aspx?

Approximately 20 million Americans now suffer from some form of thyroid disease, but experts estimate that about 13 million of them have not been diagnosed. With so many affected by a dysfunctional thyroid gland, thyroid function testing is becoming increasingly important to support both the diagnosis and management of thyroid disease. Unfortunately, controversy still exists concerning the upper limit of the TSH reference range and there is still confusion over when to use other thyroid immunoassays in the management of patients suspected of thyroid disease. Additionally, tandem mass spectrometry is rapidly emerging as a technology that could challenge labs’ reliance on traditional immunoassays for T4 and FT4. 

During this interactive webinar, you will hear the most up-to-date information on a variety of contemporary issues related to testing for thyroid disease. Our expert speakers will help you understand: 
•Where various organizations and interested parties now stand in the debate over the TSH upper reference limit 
•How to recognize and manage interferences in thyroid immunoassays 
•What’s new in testing for thyroid disease in pregnant women 
•When to use TT3, FT3, total T4, free T4, and thyroid autoantibody assays 
•Why one lab moved all of its FT4 testing to a tandem mass spec platform, and how it justifies the cost of using this technology 

Ask your questions online or via the phone during this must-attend, interactive webinar! 

The Experts: 
Laurence M. Demers, PhD, (moderator), Distinguished Professor of Pathology and Medicine, The Milton S. Hershey Medical Center at Penn State University, Hershey, PA
Steven J. Soldin, PhD, Professor in the Departments of Endocrinology and Metabolism and Pharmacology, Georgetown University, Washington, DC, and Clinical Director Endocrinology Laboratories NMS Laboratories, Willow Grove, PA
Carole A. Spencer, PhD, Professor of Medicine & Technical Director, Endocrine Services Laboratory, University of Southern California, Los Angeles, CA

Target Audience:
This program is designed for laboratorians, thyroid specialists, pathologists, laboratory directors, clinicians, endocrinologists, diagnostic manufacturers and anyone involved in the diagnosis or management of patients with thyroid disease.